On 29th July, Fosun International (00656.HK) issued a positive profit alert. Its profit attributable to owners of the parent for the first half of 2026 is expected to range from approximately RMB1.5 billion to RMB1.8 billion representing an increase of approximately 127% to 172% compared to the same period last year. The board of directors (the “Board”) considers that such increase is mainly attributable to the strong resilience demonstrated by its core industries in the first half of 2026, the steady improvement in operational quality, and the significant increase in industrial operation profit compared to the same period last year.

On 9 September 2025, Fosun International Limited (HKEX stock code: 00656, hereinafter referred to as “Fosun International”, “Fosun”, or the “Company”) held the signing ceremony for its 2025 three-year sustainability-linked syndicated loan in Hong Kong.

August 29, 2025 -- Lanvin Group (NYSE: LANV, the "Group"), a global luxury fashion group with Lanvin, Wolford, Sergio Rossi, St. John and Caruso in its portfolio of brands, today announced its unaudited results for the first half of 2025. Despite ongoing industry-wide pressures, the Group delivered performance underpinned by strong cost discipline, operational efficiency, and visible signs of recovery in the second quarter.

(Shanghai, August 27, 2025) — Fosun International Limited (00656.HK) today announced the interim results of its subsidiary, Fosun Tourism Group (the “Group”), for the six months ended June 30, 2025. During the reporting period, Fosun Tourism Group delivered steady growth, with revenue reaching a historical high and adjusted net profit increasing by over 40% year-on-year.

(Hong Kong, Shanghai, 27 August 2025) Fosun International Limited (HKEX stock code: 00656, “Fosun International”), together with its subsidiaries (“Fosun” or the “Group”), today announced its interim results for the six months ended 30 June 2025 (the “Reporting Period”).

(August 26, 2025, Shanghai, China) — On August 26, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or “the Group”; SSE: 600196, HKEX: 02196), a leading innovation-driven global healthcare company, announced its operating performance for the first half of 2025 (“the Reporting Period”).

Shanghai, China, August 25, 2025 – Henlius (2696.HK) announced its 2025 interim results. In the first half of 2025, Henlius' revenue reached about RMB2.8195 billion, representing an increase of 2.7% YoY. The gross profit of RMB2.1992 billion, up by 10.5% YoY, with a net profit reached RMB390.1 million. Operating cash flow reached RMB770.9 million, with an increase of 206.8% YoY, maintaining a steady positive inflow.

HONG KONG, August 20, 2025 -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; referred to collectively with its subsidiaries as the "Group"), a global consumer wellness group, featuring a distinguished synergistic ecosystem of business building blocks and consumer-focused approaches including Energy-Based Devices (EBD), and Injectables, alongside other complementary offerings, today announced its unaudited consolidated interim results for the six months ended June 30, 2025 (the "Reporting Period").

On 1 April 2025, Fosun International Limited (HKEX stock code: 00656, “Fosun International”), together with its subsidiaries (“Fosun” or the “Group”) held its 2024 annual results presentation in Shanghai. The results presentation was attended by Guo Guangchang, Chairman of Fosun International, Wang Qunbin, Co-Chairman of Fosun International, Chen Qiyu and Xu Xiaoliang, Co-CEOs of Fosun International, Gong Ping, CFO of Fosun International, and a number of institutional investors and analysts.